Matthew Wanat to Atrial Fibrillation
This is a "connection" page, showing publications Matthew Wanat has written about Atrial Fibrillation.
Connection Strength
0.770
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.229
-
Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
Score: 0.229
-
Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy. JAMA Cardiol. 2020 01 01; 5(1):111.
Score: 0.166
-
Novel oral anticoagulants: a review of new agents. Postgrad Med. 2013 Jul; 125(4):103-14.
Score: 0.106
-
Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: A systematic review. Expert Rev Cardiovasc Ther. 2019 Jun; 17(6):427-434.
Score: 0.040